- Home
- SLVM vs BLTE Comparison
SLVM vs BLTE Comparison
Compare SLVM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLVM
- BLTE
- Stock Information
- Founded
- SLVM 1898
- BLTE 2018
- Country
- SLVM United States
- BLTE United States
- Employees
- SLVM N/A
- BLTE N/A
- Industry
- SLVM Paper
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SLVM Basic Materials
- BLTE Health Care
- Exchange
- SLVM Nasdaq
- BLTE Nasdaq
- Market Cap
- SLVM 2.4B
- BLTE 2.1B
- IPO Year
- SLVM N/A
- BLTE 2022
- Fundamental
- Price
- SLVM $49.59
- BLTE $62.24
- Analyst Decision
- SLVM Hold
- BLTE Strong Buy
- Analyst Count
- SLVM 3
- BLTE 4
- Target Price
- SLVM $75.00
- BLTE $96.67
- AVG Volume (30 Days)
- SLVM 289.3K
- BLTE 71.7K
- Earning Date
- SLVM 08-08-2025
- BLTE 08-08-2025
- Dividend Yield
- SLVM 3.67%
- BLTE N/A
- EPS Growth
- SLVM 45.44
- BLTE N/A
- EPS
- SLVM 6.82
- BLTE N/A
- Revenue
- SLVM $3,689,000,000.00
- BLTE N/A
- Revenue This Year
- SLVM N/A
- BLTE N/A
- Revenue Next Year
- SLVM $0.11
- BLTE N/A
- P/E Ratio
- SLVM $7.18
- BLTE N/A
- Revenue Growth
- SLVM 0.11
- BLTE N/A
- 52 Week Low
- SLVM $47.85
- BLTE $43.70
- 52 Week High
- SLVM $98.02
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SLVM 43.96
- BLTE 53.07
- Support Level
- SLVM $48.95
- BLTE $59.12
- Resistance Level
- SLVM $50.19
- BLTE $62.64
- Average True Range (ATR)
- SLVM 1.29
- BLTE 2.29
- MACD
- SLVM -0.04
- BLTE 0.11
- Stochastic Oscillator
- SLVM 31.41
- BLTE 53.14
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.